CCLD vs. LFLY, GSDI, KALA, HUGE, SSKN, NRXS, NRSN, FLGC, PMCB, and AKLI
Should you be buying CareCloud stock or one of its competitors? The main competitors of CareCloud include Leafly (LFLY), Global System Dynamics (GSDI), KALA BIO (KALA), FSD Pharma (HUGE), STRATA Skin Sciences (SSKN), NeurAxis (NRXS), NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), PharmaCyte Biotech (PMCB), and Akili (AKLI). These companies are all part of the "medical" sector.
CareCloud (NASDAQ:CCLD) and Leafly (NASDAQ:LFLY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking.
CareCloud received 2 more outperform votes than Leafly when rated by MarketBeat users. Likewise, 62.50% of users gave CareCloud an outperform vote while only 37.50% of users gave Leafly an outperform vote.
Leafly has a net margin of -22.48% compared to CareCloud's net margin of -41.58%. Leafly's return on equity of 0.00% beat CareCloud's return on equity.
Leafly has lower revenue, but higher earnings than CareCloud. Leafly is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks.
In the previous week, CareCloud and CareCloud both had 2 articles in the media. CareCloud's average media sentiment score of 0.50 beat Leafly's score of 0.15 indicating that CareCloud is being referred to more favorably in the media.
10.2% of CareCloud shares are owned by institutional investors. Comparatively, 15.6% of Leafly shares are owned by institutional investors. 34.4% of CareCloud shares are owned by company insiders. Comparatively, 11.3% of Leafly shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
CareCloud has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Leafly has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
CareCloud presently has a consensus target price of $3.17, indicating a potential upside of 193.18%. Leafly has a consensus target price of $6.00, indicating a potential upside of 194.12%. Given Leafly's higher probable upside, analysts plainly believe Leafly is more favorable than CareCloud.
Summary
CareCloud beats Leafly on 10 of the 16 factors compared between the two stocks.
Get CareCloud News Delivered to You Automatically
Sign up to receive the latest news and ratings for CCLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CCLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
CareCloud Competitors List
Related Companies and Tools